» Authors » Takanori Inose

Takanori Inose

Explore the profile of Takanori Inose including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 41
Citations 574
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakajima M, Kato H, Sakai M, Sano A, Miyazaki T, Sohda M, et al.
Hepatogastroenterology . 2016 Feb; 62(140):887-91. PMID: 26902022
Background/aims: The optimal treatment for locally advanced esophageal carcinoma has not yet been determined. We report results of neoadjuvant hyperthermo-chemoradiotherapy (HCRT) using weekly low-dose docetaxel followed by surgery in patients...
2.
Miyazaki T, Ojima H, Fukuchi M, Sakai M, Sohda M, Tanaka N, et al.
Ann Surg Oncol . 2015 Feb; 22(11):3653-8. PMID: 25691281
Background: We performed a prospective, multi-institutional, phase-II, clinical trial of a docetaxel, nedaplatin, and 5-fluorouracil (DNF) regimen in patients with unresectable esophageal cancer. Our goal was to determine the efficacy...
3.
Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M, et al.
Cancer Chemother Pharmacol . 2014 Dec; 75(3):449-55. PMID: 25544126
Purpose: This phase I/II study was aimed to determine the recommended dose (RD) of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for patients with esophageal cancer and to evaluate...
4.
Sohda M, Honjyo H, Hara K, Ozawa D, Suzuki S, Tanaka N, et al.
Anticancer Res . 2014 Feb; 34(2):909-13. PMID: 24511031
Aims: L-[3-(18)F]-α-Methyltyrosine ((18)F-FAMT) has high specificity for malignant tumors on positron emission tomography (PET), and its role and potential usefulness has been previously investigated in operable esophageal carcinoma. We aimed...
5.
Miyazaki T, Tanaka N, Sano A, Suzuki S, Sakai M, Yokobori T, et al.
Anticancer Res . 2013 Nov; 33(11):5113-7. PMID: 24222157
Aim: The objective of the present study was to evaluate the significance of pre-treatment screening for patients with esophageal cancer. Patients And Methods: A retrospective evaluation of the clinical significance...
6.
Miyazaki T, Inose T, Tanaka N, Suzuki S, Hara K, Ozawa D, et al.
Kyobu Geka . 2013 Aug; 66(8 Suppl):762-6. PMID: 23917201
We reviewed the indications for re-thoracotomy after esophagectomy for esophageal cancer. Hemothorax, chylothorax, tracheobronchial injury (fistula), pneumothorax, and pyothorax were the main causes of re-thoracotomy. Indications for emergency thoracotomy were...
7.
Sano A, Sakurai S, Kato H, Suzuki S, Yokobori T, Sakai M, et al.
Oncol Rep . 2013 Apr; 29(6):2119-26. PMID: 23546020
Esophageal carcinosarcoma (ECS) is a rare malignant neoplasm associated with a poor patient prognosis. It is characterized by the presence of both malignant epithelial and mesenchymal components. Molecular-targeted therapy of...
8.
Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M, et al.
Cancer Chemother Pharmacol . 2013 Jan; 71(4):853-7. PMID: 23306309
More effective protocols are needed for unresectable and recurrent esophageal cancer. Therefore, we conducted a phase I trial to establish the recommended dose of docetaxel, nedaplatin, and 5-fluorouracil (DNF) as...
9.
Miyazaki T, Inose T, Tanaka N, Yokobori T, Suzuki S, Ozawa D, et al.
Surg Today . 2013 Jan; 43(4):353-60. PMID: 23283352
Barrett's esophagus (BE) is the premalignant lesion from which esophageal adenocarcinoma near the esophagogastric junction arises. The management of BE and the treatment of Barrett's esophageal adenocarcinoma (BEA) are important...
10.
Inose T, Miyazaki T, Suzuki S, Tanaka N, Sakai M, Sano A, et al.
Surg Today . 2012 Dec; 43(8):877-82. PMID: 23247887
Purpose: Nonspecific esophageal motility disorder (NEMD) is a vague category that includes patients with poorly defined contraction abnormalities observed during esophageal manometry. This study investigated the therapeutic effects of the...